What is the appropriate apixaban (Eliquis) dosing regimen for deep‑vein thrombosis prophylaxis after total hip or knee replacement, including duration, contraindications, and alternative agents?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Apixaban (Eliquis) for DVT Prophylaxis After Hip or Knee Replacement

For DVT prophylaxis after total hip or knee replacement, use apixaban 2.5 mg orally twice daily, starting 12-24 hours post-surgery, for 35 days after hip replacement and 12 days after knee replacement. 1, 2

Dosing Regimen

Standard dose: Apixaban 2.5 mg orally twice daily 1, 2

Timing of initiation: 12-24 hours after wound closure 3, 2

Duration:

  • Hip replacement: 35 days 3, 2
  • Knee replacement: 12 days 3, 2

This regimen is FDA-approved and supported by the most recent 2025 and 2026 guidelines 1, 4. The ADVANCE-2 and ADVANCE-3 trials demonstrated that apixaban was superior to enoxaparin 40 mg daily for VTE prevention, with lower bleeding rates 3. In hip replacement (ADVANCE-3), VTE occurred in 1.4% with apixaban versus 3.9% with enoxaparin (RR 0.36, P<0.001) 5. In knee replacement (ADVANCE-2), VTE occurred in 15% with apixaban versus 24% with enoxaparin (RR 0.62, P<0.0001) 6.

Contraindications and Precautions

Absolute contraindications: 1

  • Creatinine clearance <25 mL/min
  • Mechanical prosthetic heart valves
  • Moderate to severe mitral stenosis
  • Pregnancy and breastfeeding
  • Child-Pugh C liver disease
  • High-risk antiphospholipid syndrome (triple positive, history of arterial thrombosis)

Drug interactions requiring avoidance:

  • Potent CYP3A4 inhibitors (ketoconazole, ritonavir) 3
  • These increase plasma concentrations and are contraindicated

Renal dosing: No dose adjustment needed for CrCl ≥25 mL/min 1. Use is not recommended below this threshold.

Perioperative Management

If surgery is delayed or interrupted:

  • Stop apixaban at least 48 hours before elective procedures with moderate-to-high bleeding risk 2
  • Stop at least 24 hours before procedures with low bleeding risk 2
  • Bridging anticoagulation is not required during the 24-48 hour interruption 2

Resumption after procedures:

  • Restart when adequate hemostasis is established 2
  • For low bleeding risk surgery: resume 24 hours postoperatively 7
  • For high bleeding risk surgery: resume 48-72 hours postoperatively, consider reduced dose (2.5 mg once daily initially) 7

Alternative Agents

The 2026 ACC guidelines note that both DOACs and LMWH are appropriate for VTE prophylaxis post-THA/TKA 4. The American Society of Hematology 2019 guidelines recommend DOACs over LMWH primarily due to easier logistics and cost-effectiveness 4.

Alternatives include:

  • Rivaroxaban: 10 mg daily for 35 days (hip) or 10-14 days (knee) 1
  • Enoxaparin: 40 mg subcutaneously daily (European regimen) or 30 mg twice daily (North American regimen) 3
  • Dabigatran: 110 mg 1-4 hours post-surgery, then 220 mg once daily 1
  • Aspirin: Increasingly used but requires validation in multicenter trials 8

Important caveat: Recent observational data suggests apixaban may be associated with increased odds of VTE and bleeding complications compared to aspirin 9, though this contradicts RCT evidence. The ADVANCE-1 trial failed to meet noninferiority criteria versus enoxaparin 30 mg twice daily 10, highlighting that efficacy may vary with comparator regimen.

Clinical Pearls

  • Apixaban does not require routine laboratory monitoring 1
  • For life-threatening bleeding, use andexanet alfa for reversal 1
  • If andexanet unavailable, consider prothrombin complex concentrates 1
  • Monitor renal function postoperatively if surgery could affect kidney function 11
  • The 2026 ACC statement emphasizes that DOACs should not be used for hip fracture surgery—LMWH remains preferred 4

References

Research

Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.

The New England journal of medicine, 2010

Research

Venous Thromboembolic Prophylaxis After Total Hip and Knee Arthroplasty.

The Journal of bone and joint surgery. American volume, 2021

Research

Apixaban or enoxaparin for thromboprophylaxis after knee replacement.

The New England journal of medicine, 2009

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.